AFP L3% & Total, Hepatocellular Carcinoma




Test Mnemonic

AFPL3

CPT Codes

  • 82107 - QTY (1)

Performing Laboratory

ARUP


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
1 mLSerumSST (Gold) FrozenRemove serum from cells within 2 hours of collection.

Minimum Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
0.5 mL     

Stability

Environmental Condition Description
AmbientAfter separation from cells: 8 hours
RefrigeratedAfter separation from cells: 5 days
FrozenAfter separation from cells: 3 months (Avoid multiple freeze/thaw cycles)

Days Performed

Mon, Thu

Turnaround Time

2 - 6 days

Methodology

Name Description
Quantitative Liquid Chromatography/Immunoassay 

Reference Range

Alpha fetoprotein, L3%
Sex Age From Age To Type Range Range Unit
   Years99 YearsNormal0 - 9.9%
Alpha fetoprotein, Total
Sex Age From Age To Type Range Range Unit
   Years99 YearsNormal0 - 15ng/mL

Special Info

This test is New York DOH approved. Plasma specimens will be rejected.

Clinical Info

The purpose of this test is surveillance and monitoring of hepatocellular carcinoma. The µTASWako method is used and results cannot be used interchangeably with any other assay methods or kits. The AFP L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. For pregnant females, the result is not interpretable as a tumor marker.